These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 4741388)

  • 41. Studies on sulphone resistant strains of M. leprae in field and institutionalized cases of leprosy.
    Balakrishnan S; Seshadri PS; Neelan PN; Venkataramaniah HN; Harikrishnan S; Bhatia VN
    Lepr India; 1983 Jan; 55(1):71-5. PubMed ID: 6348413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 43. Relaspe in leprosy.
    Br Med J; 1977 Oct; 2(6092):914-5. PubMed ID: 912367
    [No Abstract]   [Full Text] [Related]  

  • 44. Does dapsone resistance really matter in the MDT era?
    Ji B
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
    [No Abstract]   [Full Text] [Related]  

  • 45. The sensitivity to Dapsone (DDS) of Mycobacterium leprae from patients with and without previous treatment.
    Shepard CC; Levy L; Fasal P
    Am J Trop Med Hyg; 1969 Mar; 18(2):258-63. PubMed ID: 4888029
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical and paraclinical aspects of secondary drug resistance to 4-4' diaminodiphenylsulfone in a population of leprosy patients in Bamako, Republic of Mali].
    Baquillon G; Ferracci C; Diallo J; Saint-Andreé P; Pattyn SR
    Acta Leprol; 1981; 85():40-52. PubMed ID: 6805234
    [No Abstract]   [Full Text] [Related]  

  • 47. Clarithromycin is bactericidal against strains of Mycobacterium leprae resistant and susceptible to dapsone and rifampin.
    Walker LL; Van Landingham RM; Shinnick TM
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):59-65. PubMed ID: 8326182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of secondary dapsone resistance in Gudiyattam Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 1. Preliminary report.
    Balraj V; Jesudasan K; Chacko CJ; Christian M; Taylor PM; Fritschi EP; Job CK
    Int J Lepr Other Mycobact Dis; 1980 Dec; 48(4):397-401. PubMed ID: 7193654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence of secondary dapsone resistance in Nepal.
    Samuel NM; Samuel S; Loudon J; Neupani K; Adiga RB
    Indian J Lepr; 1984; 56(4):823-7. PubMed ID: 6398344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dapsone-resistant Mycobacterium leprae in a patient receiving dapsone in low doses.
    Browne SG
    Int J Lepr Other Mycobact Dis; 1969; 37(3):296-301. PubMed ID: 4906048
    [No Abstract]   [Full Text] [Related]  

  • 51. Chemotherapy of leprosy for control programmes.
    World Health Organ Tech Rep Ser; 1982; 675():1-33. PubMed ID: 6806990
    [No Abstract]   [Full Text] [Related]  

  • 52. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
    Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
    Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proven primary dapsone resistance in leprosy--a case report.
    Waters MF; Laing AB; Rees RJ
    Lepr Rev; 1978 Jun; 49(2):127-30. PubMed ID: 661480
    [No Abstract]   [Full Text] [Related]  

  • 54. The treatment of leprosy in Papua New Guinea.
    Reé GH
    P N G Med J; 1982 Sep; 25(3):142. PubMed ID: 6961638
    [No Abstract]   [Full Text] [Related]  

  • 55. [Current therapeutics in leprosy: resistance--therapeutic regimens--control strategy].
    Nebout M
    Acta Leprol; 1983; 1(3):151-8. PubMed ID: 6359803
    [No Abstract]   [Full Text] [Related]  

  • 56. [. 663 (G 30320 "Geigy"), a new chemotherapeutic agent against leprosy].
    Vischer WA
    Schweiz Med Wochenschr; 1967 Mar; 97(10):308. PubMed ID: 5585384
    [No Abstract]   [Full Text] [Related]  

  • 57. Social and personality factors in dapsone resistant patients.
    John JK; Pannikar VK; Verghese A; Christian M
    Lepr India; 1983 Jan; 55(1):100-6. PubMed ID: 6876750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The histoid leproma. Its characteristics and significance.
    Rodriguez JN
    Int J Lepr Other Mycobact Dis; 1969; 37(1):1-21. PubMed ID: 5817631
    [No Abstract]   [Full Text] [Related]  

  • 59. Persister M. leprae after introductory rifampicin followed by dapsone therapy.
    Sreevatsa ; Girdhar BK; Desikan KV
    Lepr India; 1981 Jul; 53(3):350-3. PubMed ID: 7278139
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dapsone in leprosy.
    Baker IA; Jopling WH
    Trop Doct; 1974 Jul; 4(3):140. PubMed ID: 4851263
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.